309 related articles for article (PubMed ID: 29523784)
1. MYC-driven epigenetic reprogramming favors the onset of tumorigenesis by inducing a stem cell-like state.
Poli V; Fagnocchi L; Fasciani A; Cherubini A; Mazzoleni S; Ferrillo S; Miluzio A; Gaudioso G; Vaira V; Turdo A; Gaggianesi M; Chinnici A; Lipari E; Bicciato S; Bosari S; Todaro M; Zippo A
Nat Commun; 2018 Mar; 9(1):1024. PubMed ID: 29523784
[TBL] [Abstract][Full Text] [Related]
2. Targeting Oncogenic Super Enhancers in MYC-Dependent AML Using a Small Molecule Activator of NR4A Nuclear Receptors.
Call SG; Duren RP; Panigrahi AK; Nguyen L; Freire PR; Grimm SL; Coarfa C; Conneely OM
Sci Rep; 2020 Feb; 10(1):2851. PubMed ID: 32071334
[TBL] [Abstract][Full Text] [Related]
3. The epigenetic modifier JMJD6 is amplified in mammary tumors and cooperates with c-Myc to enhance cellular transformation, tumor progression, and metastasis.
Aprelikova O; Chen K; El Touny LH; Brignatz-Guittard C; Han J; Qiu T; Yang HH; Lee MP; Zhu M; Green JE
Clin Epigenetics; 2016; 8():38. PubMed ID: 27081402
[TBL] [Abstract][Full Text] [Related]
4. Long-term culture following ES-like gene-induced reprogramming elicits an aggressive phenotype in mutated cholangiocellular carcinoma cells.
Nagai K; Ishii H; Miyoshi N; Hoshino H; Saito T; Sato T; Tomimaru Y; Kobayashi S; Nagano H; Sekimoto M; Doki Y; Mori M
Biochem Biophys Res Commun; 2010 Apr; 395(2):258-63. PubMed ID: 20381452
[TBL] [Abstract][Full Text] [Related]
5. Hsp90α Mediates BMI1 Expression in Breast Cancer Stem/Progenitor Cells through Facilitating Nuclear Translocation of c-Myc and EZH2.
Lee YC; Chang WW; Chen YY; Tsai YH; Chou YH; Tseng HC; Chen HL; Wu CC; Chang-Chien J; Lee HT; Yang HF; Wang BY
Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28914785
[TBL] [Abstract][Full Text] [Related]
6. p53 Loss in Breast Cancer Leads to Myc Activation, Increased Cell Plasticity, and Expression of a Mitotic Signature with Prognostic Value.
Santoro A; Vlachou T; Luzi L; Melloni G; Mazzarella L; D'Elia E; Aobuli X; Pasi CE; Reavie L; Bonetti P; Punzi S; Casoli L; Sabò A; Moroni MC; Dellino GI; Amati B; Nicassio F; Lanfrancone L; Pelicci PG
Cell Rep; 2019 Jan; 26(3):624-638.e8. PubMed ID: 30650356
[TBL] [Abstract][Full Text] [Related]
7. Resistance to everolimus driven by epigenetic regulation of MYC in ER+ breast cancers.
Bihani T; Ezell SA; Ladd B; Grosskurth SE; Mazzola AM; Pietras M; Reimer C; Zinda M; Fawell S; D'Cruz CM
Oncotarget; 2015 Feb; 6(4):2407-20. PubMed ID: 25537515
[TBL] [Abstract][Full Text] [Related]
8. Gene Transactivation and Transrepression in MYC-Driven Cancers.
Scafuro M; Capasso L; Carafa V; Altucci L; Nebbioso A
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33801599
[No Abstract] [Full Text] [Related]
9. Oncogenic translation directs spliceosome dynamics revealing an integral role for SF3A3 in breast cancer.
Cieśla M; Ngoc PCT; Cordero E; Martinez ÁS; Morsing M; Muthukumar S; Beneventi G; Madej M; Munita R; Jönsson T; Lövgren K; Ebbesson A; Nodin B; Hedenfalk I; Jirström K; Vallon-Christersson J; Honeth G; Staaf J; Incarnato D; Pietras K; Bosch A; Bellodi C
Mol Cell; 2021 Apr; 81(7):1453-1468.e12. PubMed ID: 33662273
[TBL] [Abstract][Full Text] [Related]
10. Emerging roles of Myc in stem cell biology and novel tumor therapies.
Yoshida GJ
J Exp Clin Cancer Res; 2018 Jul; 37(1):173. PubMed ID: 30053872
[TBL] [Abstract][Full Text] [Related]
11. Gene expression profiling of MYC-driven tumor signatures in porcine liver stem cells by transcriptome sequencing.
Aravalli RN; Talbot NC; Steer CJ
World J Gastroenterol; 2015 Feb; 21(7):2011-29. PubMed ID: 25717234
[TBL] [Abstract][Full Text] [Related]
12. Deterministic Somatic Cell Reprogramming Involves Continuous Transcriptional Changes Governed by Myc and Epigenetic-Driven Modules.
Zviran A; Mor N; Rais Y; Gingold H; Peles S; Chomsky E; Viukov S; Buenrostro JD; Scognamiglio R; Weinberger L; Manor YS; Krupalnik V; Zerbib M; Hezroni H; Jaitin DA; Larastiaso D; Gilad S; Benjamin S; Gafni O; Mousa A; Ayyash M; Sheban D; Bayerl J; Aguilera-Castrejon A; Massarwa R; Maza I; Hanna S; Stelzer Y; Ulitsky I; Greenleaf WJ; Tanay A; Trumpp A; Amit I; Pilpel Y; Novershtern N; Hanna JH
Cell Stem Cell; 2019 Feb; 24(2):328-341.e9. PubMed ID: 30554962
[TBL] [Abstract][Full Text] [Related]
13. The involvement of a Nanog, Klf4 and c-Myc transcriptional circuitry in the intertwining between neoplastic progression and reprogramming.
Marzi I; Cipolleschi MG; D'Amico M; Stivarou T; Rovida E; Vinci MC; Pandolfi S; Dello Sbarba P; Stecca B; Olivotto M
Cell Cycle; 2013 Jan; 12(2):353-64. PubMed ID: 23287475
[TBL] [Abstract][Full Text] [Related]
14. ADHFE1 is a breast cancer oncogene and induces metabolic reprogramming.
Mishra P; Tang W; Putluri V; Dorsey TH; Jin F; Wang F; Zhu D; Amable L; Deng T; Zhang S; Killian JK; Wang Y; Minas TZ; Yfantis HG; Lee DH; Sreekumar A; Bustin M; Liu W; Putluri N; Ambs S
J Clin Invest; 2018 Jan; 128(1):323-340. PubMed ID: 29202474
[TBL] [Abstract][Full Text] [Related]
15. Histone demethylase PHF8 promotes epithelial to mesenchymal transition and breast tumorigenesis.
Shao P; Liu Q; Maina PK; Cui J; Bair TB; Li T; Umesalma S; Zhang W; Qi HH
Nucleic Acids Res; 2017 Feb; 45(4):1687-1702. PubMed ID: 27899639
[TBL] [Abstract][Full Text] [Related]
16. Metabolic reprogramming in triple-negative breast cancer through Myc suppression of TXNIP.
Shen L; O'Shea JM; Kaadige MR; Cunha S; Wilde BR; Cohen AL; Welm AL; Ayer DE
Proc Natl Acad Sci U S A; 2015 Apr; 112(17):5425-30. PubMed ID: 25870263
[TBL] [Abstract][Full Text] [Related]
17. c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations.
D'Cruz CM; Gunther EJ; Boxer RB; Hartman JL; Sintasath L; Moody SE; Cox JD; Ha SI; Belka GK; Golant A; Cardiff RD; Chodosh LA
Nat Med; 2001 Feb; 7(2):235-9. PubMed ID: 11175856
[TBL] [Abstract][Full Text] [Related]
18. Piwil2 is reactivated by HPV oncoproteins and initiates cell reprogramming via epigenetic regulation during cervical cancer tumorigenesis.
Feng D; Yan K; Zhou Y; Liang H; Liang J; Zhao W; Dong Z; Ling B
Oncotarget; 2016 Oct; 7(40):64575-64588. PubMed ID: 27602489
[TBL] [Abstract][Full Text] [Related]
19. NCoR/SMRT co-repressors cooperate with c-MYC to create an epigenetic barrier to somatic cell reprogramming.
Zhuang Q; Li W; Benda C; Huang Z; Ahmed T; Liu P; Guo X; Ibañez DP; Luo Z; Zhang M; Abdul MM; Yang Z; Yang J; Huang Y; Zhang H; Huang D; Zhou J; Zhong X; Zhu X; Fu X; Fan W; Liu Y; Xu Y; Ward C; Khan MJ; Kanwal S; Mirza B; Tortorella MD; Tse HF; Chen J; Qin B; Bao X; Gao S; Hutchins AP; Esteban MA
Nat Cell Biol; 2018 Apr; 20(4):400-412. PubMed ID: 29531310
[TBL] [Abstract][Full Text] [Related]
20. Long non-coding RNA FGF13-AS1 inhibits glycolysis and stemness properties of breast cancer cells through FGF13-AS1/IGF2BPs/Myc feedback loop.
Ma F; Liu X; Zhou S; Li W; Liu C; Chadwick M; Qian C
Cancer Lett; 2019 May; 450():63-75. PubMed ID: 30771425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]